Francis Ho

Amperesand’s medium voltage power conversion solutions enable fast, efficient, and resilient electrification on a global scale for critical power consumers like AI datacenters and industrial loads. Combining next generation Solid State Transformers, cutting edge controls, and AI-first software, Amperesand is building the cornerstone of our future power infrastructure. Our technology was pioneered by the Energy Research Institute at Singapore’s Nanyang Technological University (NTU) and spun out by Xora Innovation.

Discover the limitless potential of human induced pluripotent stem cells (iPSCs) for groundbreaking research at Greenstone, a leading Bay Area biotech company. We combine cutting-edge technology with AI, computational biology, and pharmacogenomics to accelerate drug discovery and development, transforming the future of therapeutics. Our vision is to transform drug discovery from a slow, sequential, and high-failure process into a rapid, integrated, and novel computational platform. By harnessing the power of iPSCs and our advanced technologies, we revolutionize the traditional drug discovery paradigm, paving the way for a faster, more efficient approach. With our curated and diverse collection of iPSCs, sourced from both healthy individuals and those affected by various diseases, we offer a comprehensive platform for disease modeling, uncovering novel mechanisms, and advancing drug discovery. Our high-quality iPSCs provide researchers with patient-specific and disease-specific cells, enabling the development of personalized treatment strategies. At Greenstone, collaboration and innovation are at the core of our values. We proudly offer our iPSCs to academic investigators free of cost, fostering an environment of shared knowledge and progress. Together, we can unlock new insights, accelerate drug discovery, and shape the future of personalized medicine. Join us on the frontier of biomedical research and tap into the immense potential of iPSCs. Together, lets transform drug discovery into a rapid, integrated, and computational platform that propels us towards groundbreaking therapeutics. #Biotech #iPSCs #DrugDiscovery #BiomedicalResearch #PersonalizedMedicine #Innovation

Our AI can prognosticate patient outcomes & personalize treatment in localized prostate cancer. Five Phase III randomized trials were used to develop prognostic and predictive AI biomarkers.

Nearfield Instruments brings together the most creative minds in science and technology to develop, produce and market revolutionary high throughput scanning probe microscopy systems, enabling atom-scale resolution 3D metrology at industry-level throughput. We design, develop, integrate, market and service these advanced metrology machines, which enable our customers – the world’s leading chipmakers – to increase the production yields, and thus, functionality of their microchips. In this way NFI contributes to the development of smaller, more powerful consumer electronics.

Ingonyama is a next-generation semiconductor company, focusing on Zero-Knowledge Proof hardware acceleration. Using a broad, multidisciplinary approach and a deep understanding of the ZK landscape, we focus on finding and solving computational bottlenecks in ZKPs. Our goal is to radically improve the performance of Zero-Knowledge (ZK) Provers by designing hardware optimized for ZK computation.

We are the first in class pre-clinical translational biophysics company focusing on the discovery of novel therapeutics against intrinsically disordered targets.

Our vision is a world where genomic information is fully accessible, understandable and integrated into health and well being. As a leading telegenetics care delivery company, we make genetic care accessible and actionable for patients throughout the U.S. and Canada through seven-day a week access to genetic services. By partnering with health systems, providers, labs and biopharmaceutical companies, we expand the reach and impact of genomic medicine. We help our partners deliver clinical risk assessments for patients, genetic test recommendations and ordering, pre- and post-test genetic counseling through our team of expert genetic counselors, and personalized care plans. Our advisory services team uses an evidence-based approach to help partners evaluate and develop scalable, efficient and successful genetics programs.

Semiconductor interconnects

IonQ, Inc. [NYSE: IONQ] is the world’s leading quantum platform and merchant supplier - delivering integrated quantum solutions across computing, networking, sensing, and security. IonQ’s newest generation of quantum computers, the forthcoming IonQ Tempo, will be the latest in a line of cutting-edge systems that have been helping customers and partners including Amazon Web Services, AstraZeneca, and NVIDIA achieve 20x performance results and accelerate innovation in drug discovery, materials science, financial modeling, logistics, cybersecurity, and defense. In 2025, the company achieved 99.99% two-qubit gate fidelity, setting a world record in quantum computing performance. Headquartered in College Park, Maryland, IonQ has operations in California, Colorado, Massachusetts, Tennessee, Washington, Italy, South Korea, Sweden, Switzerland, Toronto, and the United Kingdom. Our quantum computing services are available through all major cloud providers, while we also meet the needs of networking and sensing customers across land, sea, air, and space. IonQ is making quantum platforms more accessible and impactful than ever before. Learn more at IonQ.com.

AI Fund is a venture studio. We collaborate with entrepreneurs, venture funds, and corporate partners to create great companies that move humanity forward. Founded by Andrew Ng, AI Fund is backed by over $370 million. As a venture studio, we work alongside entrepreneurs, venture funds, and corporate partners to build new companies rapidly and increase their odds of success. The studio is supported by top-tier VCs and partners including Sequoia Capital, NEA, Nikkei, and AES.

Amperesand’s medium voltage power conversion solutions enable fast, efficient, and resilient electrification on a global scale for critical power consumers like AI datacenters and industrial loads. Combining next generation Solid State Transformers, cutting edge controls, and AI-first software, Amperesand is building the cornerstone of our future power infrastructure. Our technology was pioneered by the Energy Research Institute at Singapore’s Nanyang Technological University (NTU) and spun out by Xora Innovation.

Discover the limitless potential of human induced pluripotent stem cells (iPSCs) for groundbreaking research at Greenstone, a leading Bay Area biotech company. We combine cutting-edge technology with AI, computational biology, and pharmacogenomics to accelerate drug discovery and development, transforming the future of therapeutics. Our vision is to transform drug discovery from a slow, sequential, and high-failure process into a rapid, integrated, and novel computational platform. By harnessing the power of iPSCs and our advanced technologies, we revolutionize the traditional drug discovery paradigm, paving the way for a faster, more efficient approach. With our curated and diverse collection of iPSCs, sourced from both healthy individuals and those affected by various diseases, we offer a comprehensive platform for disease modeling, uncovering novel mechanisms, and advancing drug discovery. Our high-quality iPSCs provide researchers with patient-specific and disease-specific cells, enabling the development of personalized treatment strategies. At Greenstone, collaboration and innovation are at the core of our values. We proudly offer our iPSCs to academic investigators free of cost, fostering an environment of shared knowledge and progress. Together, we can unlock new insights, accelerate drug discovery, and shape the future of personalized medicine. Join us on the frontier of biomedical research and tap into the immense potential of iPSCs. Together, lets transform drug discovery into a rapid, integrated, and computational platform that propels us towards groundbreaking therapeutics. #Biotech #iPSCs #DrugDiscovery #BiomedicalResearch #PersonalizedMedicine #Innovation

Our AI can prognosticate patient outcomes & personalize treatment in localized prostate cancer. Five Phase III randomized trials were used to develop prognostic and predictive AI biomarkers.

Nearfield Instruments brings together the most creative minds in science and technology to develop, produce and market revolutionary high throughput scanning probe microscopy systems, enabling atom-scale resolution 3D metrology at industry-level throughput. We design, develop, integrate, market and service these advanced metrology machines, which enable our customers – the world’s leading chipmakers – to increase the production yields, and thus, functionality of their microchips. In this way NFI contributes to the development of smaller, more powerful consumer electronics.

Ingonyama is a next-generation semiconductor company, focusing on Zero-Knowledge Proof hardware acceleration. Using a broad, multidisciplinary approach and a deep understanding of the ZK landscape, we focus on finding and solving computational bottlenecks in ZKPs. Our goal is to radically improve the performance of Zero-Knowledge (ZK) Provers by designing hardware optimized for ZK computation.